Pyng enhanced infusion system
This article was originally published in Clinica
The US FDA has awarded special 510(k) clearance to Canadian firm Pyng Medical, allowing the sale of an improved version of the FAST1 intraosseous infusion system. Vancouver-based Pyng claims that the device is the most rapid, reliable and safe alternative to IV infusion, and provides lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims. The improved system has an infusion tube that no longer requires the use of a removal tool; Pyng said that the improvements reflect feedback from key customers based on real-life applications in the battlefield and emergency environments. The product will be launched in the US immediately.
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.